<DOC>
	<DOCNO>NCT02601157</DOCNO>
	<brief_summary>We little experience coronary intervention recently introduce new drug-eluting stent ( DES ) platform , despite great anticipation , optimal duration dual antiplatelet therapy ( DAPT ) stent system still need establish . With 2x2 factorial design patient stable angina silent ischemia , investigator formulate head-to-head randomized comparison sirolimus-eluting Orsiro stent biodegradable polymer polymer-free stent platform antiproliferative agent , Coroflex ISAR stent system . At time , clopidogrel treatment add aspirin 3-months period stenting , abbreviate duration DAPT compare conventional 1-year mandatory DAPT regimen 1:1 randomized stratification . 1-year target lesion failure ( TLF ) composite cardiac death , target vessel related myocardial infarction clinically drive target lesion revascularization identify primary efficacy outcome . And addition TLF , definite probable stent thrombosis major bleed event also count composite outcome net adverse clinical event ( NACEs ) comprehensively adjudicate efficacy safety outcomes accord difference DAPT duration . With trial , able get clear insight behavior newer DES platform . Reference data shorten mandatory DAPT regimen also delineate selected patient , might helpful need .</brief_summary>
	<brief_title>Harmonizing Optimal Strategy Treatment Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms Abbreviated Dual Antiplatelet Therapy ( HOST-IDEA ) Trial</brief_title>
	<detailed_description>Every antiplatelet-naïve patient undergo elective procedure give 300 mg aspirin load dose one P2Y12 receptor inhibitor ( e.g. , 600 mg clopidogrel , 60 mg prasugrel 180 mg ticagrelor ) preferably ≥2 hour intervention . These load dos waive chronic antiplatelet user , prasugrel ticagrelor use instead clopidogrel . Choice P2Y12 inhibitor leave responsible physician ' discretion , decision base patient/lesional characteristic .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients de novo stenotic lesion suitable coronary stenting drugeluting stent 1 . High risk profile ischemic adverse event A. STsegment elevation myocardial infarction ( STEMI ) B . Patients cardiogenic shock concomitant severe decompensated heart failure C. Myocardial infarction stent thrombosis spite maintenance antiplatelet therapy D. Restenosis stented segment previous site balloon angioplasty 2 . Patients follow allocate DAPT schedule due plan surgery elective procedure within 3 month stenting 3 . Recent history major surgery evident event gastrointestinal bleeding within 1 month procedure 4 . Patients anticoagulation therapy warfarin anticoagulant 5 . Life expectancy less 1 year ( malignancy chronic systemic disease ) 6 . Pregnant woman 7 . Past history allergy contraindication follow medications/materials : aspirin , clopidogrel , heparin , cobalt chromium , sirolimus</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>stent</keyword>
	<keyword>polymer</keyword>
	<keyword>antiplatelet therapy</keyword>
	<keyword>clopidogrel</keyword>
</DOC>